[go: up one dir, main page]

NO20082338L - Pyrimidinderivater for behandling av avvikende cellevekst - Google Patents

Pyrimidinderivater for behandling av avvikende cellevekst

Info

Publication number
NO20082338L
NO20082338L NO20082338A NO20082338A NO20082338L NO 20082338 L NO20082338 L NO 20082338L NO 20082338 A NO20082338 A NO 20082338A NO 20082338 A NO20082338 A NO 20082338A NO 20082338 L NO20082338 L NO 20082338L
Authority
NO
Norway
Prior art keywords
treatment
cell growth
aberrant cell
pyrimidine derivatives
mammals
Prior art date
Application number
NO20082338A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Michael Joseph Luzzio
Donn Gregory Wishka
Joel Thomas Arcari
Arthur Douglas Brosius
Kendra Louise Nelson
Gonghua Pan
Jr James Alfred Southers
Jun Xiao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20082338L publication Critical patent/NO20082338L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det beskrives en forbindelse av formel (I) eller et farmasøytisk akseptabelt salt derav, hvor Ar er en gruppe av formel (II) og salter derav. Slike pyrimidinderivater er nyttige i behandling av avvikende cellevekst, så som cancer, i pattedyr. Oppfinnelsen vedrører også en fremgangsmåte for å anvende slike forbindelser i behandling av avvikende cellevekst i pattedyr, spesielt mennesker, og farmasøytiske sammensetninger inneholdende slike forbindelser.
NO20082338A 2005-12-21 2008-05-22 Pyrimidinderivater for behandling av avvikende cellevekst NO20082338L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (en) 2005-12-21 2006-12-11 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NO20082338L true NO20082338L (no) 2008-06-25

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082338A NO20082338L (no) 2005-12-21 2008-05-22 Pyrimidinderivater for behandling av avvikende cellevekst

Country Status (30)

Country Link
US (1) US7820648B2 (no)
EP (1) EP1966207A2 (no)
JP (1) JP4332590B2 (no)
KR (1) KR101060051B1 (no)
CN (1) CN101346380B (no)
AP (1) AP2008004488A0 (no)
AR (1) AR058399A1 (no)
AU (1) AU2006327871A1 (no)
BR (1) BRPI0620324A2 (no)
CA (1) CA2634646C (no)
CR (1) CR10095A (no)
DO (1) DOP2006000289A (no)
EA (1) EA014551B1 (no)
EC (1) ECSP088563A (no)
GT (1) GT200600517A (no)
HN (1) HN2006042221A (no)
IL (1) IL191555A0 (no)
MA (1) MA30075B1 (no)
ME (1) MEP0908A (no)
NL (1) NL2000375C2 (no)
NO (1) NO20082338L (no)
PE (1) PE20071138A1 (no)
RS (1) RS20080272A (no)
SV (1) SV2008002969A (no)
TN (1) TNSN08270A1 (no)
TW (1) TW200736258A (no)
UA (1) UA89123C2 (no)
UY (1) UY30051A1 (no)
WO (1) WO2007072158A2 (no)
ZA (1) ZA200804488B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
ES2633318T3 (es) * 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
ES2593486T3 (es) 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
EP2183225A1 (en) 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
US8372974B2 (en) * 2008-03-20 2013-02-12 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
EA020807B1 (ru) 2008-06-17 2015-01-30 Астразенека Аб Соединения пиридина
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
BR112013024378A2 (pt) 2011-03-24 2016-12-13 Chemilia Ab novos derivados de pirimidina
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2794598A1 (en) 2011-12-23 2014-10-29 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
CA3204383A1 (en) * 2021-01-07 2022-07-14 Rima AL-AWAR Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
EP4277902A4 (en) * 2021-01-07 2024-12-18 Ontario Institute for Cancer Research (OICR) ISOINDOLINONE-AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE440087T1 (de) * 2003-01-30 2009-09-15 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EP1751143A1 (en) * 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células

Also Published As

Publication number Publication date
CR10095A (es) 2008-07-17
EA014551B1 (ru) 2010-12-30
CN101346380B (zh) 2012-02-29
KR20080077026A (ko) 2008-08-20
CA2634646C (en) 2012-04-10
WO2007072158A8 (en) 2008-08-14
TW200736258A (en) 2007-10-01
MEP0908A (xx) 2010-02-10
EP1966207A2 (en) 2008-09-10
HN2006042221A (es) 2010-01-18
NL2000375A1 (nl) 2007-06-25
IL191555A0 (en) 2008-12-29
US20080234303A1 (en) 2008-09-25
WO2007072158A2 (en) 2007-06-28
UY30051A1 (es) 2007-07-31
ECSP088563A (es) 2008-07-30
MA30075B1 (fr) 2008-12-01
JP2009520807A (ja) 2009-05-28
TNSN08270A1 (fr) 2009-10-30
WO2007072158A3 (en) 2007-12-27
ZA200804488B (en) 2009-05-27
SV2008002969A (es) 2010-08-17
KR101060051B1 (ko) 2011-08-29
AP2008004488A0 (en) 2008-06-30
AU2006327871A1 (en) 2007-06-28
CN101346380A (zh) 2009-01-14
CA2634646A1 (en) 2007-06-28
DOP2006000289A (es) 2007-07-31
BRPI0620324A2 (pt) 2011-11-08
RS20080272A (sr) 2009-07-15
EA200801287A1 (ru) 2008-10-30
GT200600517A (es) 2007-09-13
NL2000375C2 (nl) 2008-01-03
US7820648B2 (en) 2010-10-26
AR058399A1 (es) 2008-01-30
PE20071138A1 (es) 2007-12-29
UA89123C2 (ru) 2009-12-25
JP4332590B2 (ja) 2009-09-16

Similar Documents

Publication Publication Date Title
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY148636A (en) Benzimidazole derivatives
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2011027249A3 (en) Benzimidazole derivatives
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
TW200833675A (en) Nicotinamide derivatives
WO2007135527A3 (en) Benzimidazolyl compounds
NO20092033L (no) Nye forbindelser
NO20082496L (no) Pyrazinderivater
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20054852L (no) GFAT inhibitorer
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
WO2009096667A3 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application